We are live on ! Find out more
KPTI icon

Karyopharm Therapeutics
KPTI

137 hedge funds and large institutions have $145M invested in Karyopharm Therapeutics in 2023 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 43 increasing their positions, 41 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

153% more call options, than puts

Call options by funds: $613K | Put options by funds: $242K

36% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 22

6% more funds holding

Funds holding: 129 → 137 (+8)

5% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 41

0.38% less ownership

Funds ownership: 5.15% → 4.77% (-0.38%)

57% less capital invested

Capital invested by funds: $340M → $145M (-$195M)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
137
Holders Change
+8
Holders Change %
+6.2%
% of All Funds
2.15%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
30
Increased
43
Reduced
41
Closed
22
Calls
$613K
Puts
$242K
Net Calls
+$371K
Net Calls Change
-$148K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$7.08M
2
ECM
ExodusPoint Capital Management
New York
+$6.84M
3
ACM
AIGH Capital Management
Maryland
+$5.09M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$3.39M
5
Millennium Management
Millennium Management
New York
+$3.27M

Top Sellers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
-$22.9M
2
RCMNY
Rubric Capital Management (New York)
New York
-$10.1M
3
Bank of America
Bank of America
North Carolina
-$5.23M
4
Barclays
Barclays
United Kingdom
-$5M
5
N
Nuveen
North Carolina
-$3.78M
Name Holding Trade Value Shares
Change 		Change in
Stake
Jane Street
26
Jane Street
New York
$1.19M +$1.9M +44,158 New
Bank of New York Mellon
27
Bank of New York Mellon
New York
$1.18M +$592K +13,743 +45%
UOC
28
UBS O'Connor
Illinois
$1.09M +$37K +860 +2%
D.E. Shaw & Co
29
D.E. Shaw & Co
New York
$1.07M +$138K +3,211 +9%
Wellington Management Group
30
Wellington Management Group
Massachusetts
$1.01M +$941K +21,850 +140%
JGC
31
J. Goldman & Co
New York
$966K +$1.55M +35,983 New
SCM
32
Silverarc Capital Management
Massachusetts
$929K -$2.94M -68,163 -66%
PIM
33
Platinum Investment Management
Australia
$895K +$1.44M +33,333 New
Alyeska Investment Group
34
Alyeska Investment Group
Illinois
$862K – – –
N
35
Nuveen
North Carolina
$830K -$3.78M -87,667 -74%
BNP Paribas Financial Markets
36
BNP Paribas Financial Markets
France
$825K +$263K +6,100 +25%
WVP
37
Worth Venture Partners
New Jersey
$798K +$1.28M +29,732 New
UBS Group
38
UBS Group
Switzerland
$783K +$790K +18,345 +169%
Morgan Stanley
39
Morgan Stanley
New York
$756K -$874K -20,292 -42%
IC
40
Ikarian Capital
Texas
$716K +$287K +6,667 +33%
XT
41
XTX Topco
Cayman Islands
$687K +$1.1M +25,590 New
Macquarie Group
42
Macquarie Group
Australia
$680K – – –
PL
43
Parkwood LLC
Ohio
$669K +$2.87M +66,667 New
Ameriprise
44
Ameriprise
Minnesota
$645K +$294K +6,820 +40%
Two Sigma Investments
45
Two Sigma Investments
New York
$622K +$998K +23,170 New
Bank of America
46
Bank of America
North Carolina
$602K -$5.23M -121,423 -84%
Charles Schwab
47
Charles Schwab
California
$545K +$234K +5,443 +37%
BC
48
Birchview Capital
Vermont
$521K – – –
Fidelity Investments
49
Fidelity Investments
Massachusetts
$476K +$434K +10,073 +131%
Two Sigma Advisers
50
Two Sigma Advisers
New York
$466K -$406K -9,420 -35%
1
2
3 4 5

KPTI Hedge Fund Activity: Q2 2023 in Review

137 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q2 2023, worth a combined $145M — down 57% from $340M a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new KPTI positions and 22 closed out — a net gain of 8 holders — while 43 added to existing stakes and 41 trimmed.

The largest buyer was BlackRock, adding an estimated $7.08M. The largest seller was State Street, cutting an estimated $22.9M.

  • 137 institutional investors held Karyopharm Therapeutics (KPTI) as of Q2 2023, up from 129 in Q1 2023.
  • Funds reported $145M of Karyopharm Therapeutics stock for Q2 2023, down 57% quarter-over-quarter.
  • 30 funds opened new Karyopharm Therapeutics positions in Q2 2023 and 22 closed out, a net change of +8 holders.
  • The largest Karyopharm Therapeutics buyer in Q2 2023 was BlackRock, an estimated $7.08M added.
  • The largest Karyopharm Therapeutics seller in Q2 2023 was State Street, an estimated $22.9M sold.

Based on aggregated 13F filings for Q2 2023.